patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_270177 | REC_0011401 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 14.4 | 72 | female | 1 | 15 | 5.4 | 0 | sotorasib 960 mg daily | 19.4 | false | MSI-H | 2026-03-15T05:35:59.715467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644288 | REC_0011402 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 13.1 | 82 | female | 2 | 21 | 6.8 | 2 | osimertinib 80 mg daily | 9.8 | false | MSI-H | 2026-03-15T05:35:59.716062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840349 | REC_0011403 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 15 | 66 | female | 0 | 17 | 5.6 | 7 | alectinib 600 mg BID | 10.2 | true | MSS | 2026-03-15T05:35:59.716502+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329430 | REC_0011404 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 15.7 | 73 | female | 0 | 9 | 6 | 1 | entrectinib 600 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:59.716764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863410 | REC_0011405 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 9.9 | 69 | female | 0 | 10 | 6.5 | 4 | sotorasib 960 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:59.717004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263203 | REC_0011406 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 15.1 | 66 | male | 1 | 18 | 5.5 | 2 | osimertinib 80 mg daily | 25.6 | false | MSS | 2026-03-15T05:35:59.717253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186357 | REC_0011407 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 7.1 | 72 | female | 1 | 62 | 6.3 | 2 | pembrolizumab 200 mg q3w | 21.2 | true | MSS | 2026-03-15T05:35:59.717497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638008 | REC_0011408 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 1.6 | 58 | female | 1 | 21 | 4.1 | 2 | pembrolizumab 200 mg q3w | 23.7 | true | MSS | 2026-03-15T05:35:59.717742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804446 | REC_0011409 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 4.5 | 71 | male | 2 | 77 | 5.5 | 5 | pembrolizumab 200 mg q3w | 7.2 | true | MSS | 2026-03-15T05:35:59.717988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861282 | REC_0011410 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 15.5 | 66 | female | 0 | 15 | 7.9 | 1 | osimertinib 80 mg daily | 9.1 | true | MSS | 2026-03-15T05:35:59.718231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164697 | REC_0011411 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.7 | 68 | female | 0 | 28 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.5 | false | MSS | 2026-03-15T05:35:59.718469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577120 | REC_0011412 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.6 | 74 | male | 2 | 20 | 5.9 | 2 | osimertinib 80 mg daily | 32 | true | MSS | 2026-03-15T05:35:59.718722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393989 | REC_0011413 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 13 | 77 | male | 1 | 27 | 4.8 | 1 | osimertinib 80 mg daily | 16.6 | true | MSS | 2026-03-15T05:35:59.718977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214248 | REC_0011414 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14.4 | 45 | female | 0 | 17 | 6.7 | 5 | osimertinib 80 mg daily | 16.9 | false | MSI-H | 2026-03-15T05:35:59.719242+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537512 | REC_0011415 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 12.2 | 87 | female | 1 | 14 | 5.7 | 2 | alectinib 600 mg BID | 24.8 | true | MSI-H | 2026-03-15T05:35:59.719636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557810 | REC_0011416 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 13.7 | 65 | female | 1 | 18 | 3.9 | 5 | alectinib 600 mg BID | 11.4 | false | MSI-H | 2026-03-15T05:35:59.719905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968090 | REC_0011417 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 18.4 | 68 | female | 0 | 14 | 6.5 | 2 | sotorasib 960 mg daily | 25.6 | true | MSI-H | 2026-03-15T05:35:59.720206+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213396 | REC_0011418 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 25 | 65 | male | 0 | 8 | 7.1 | 6 | sotorasib 960 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:59.720474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105001 | REC_0011419 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 16.1 | 69 | male | 0 | 15 | 5.2 | 1 | sotorasib 960 mg daily | 15 | true | MSS | 2026-03-15T05:35:59.720734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250119 | REC_0011420 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 12.5 | 75 | female | 1 | 5 | 7 | 4 | sotorasib 960 mg daily | 18.4 | false | MSI-H | 2026-03-15T05:35:59.721095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650966 | REC_0011421 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 9.5 | 59 | male | 1 | 18 | 5.1 | 4 | osimertinib 80 mg daily | 10.2 | true | MSS | 2026-03-15T05:35:59.721374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790262 | REC_0011422 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 13 | 76 | female | 2 | 10 | 6 | 6 | pembrolizumab 200 mg q3w | 13.2 | false | MSS | 2026-03-15T05:35:59.721631+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556138 | REC_0011423 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 8 | 65 | female | 1 | 4 | 5.8 | 5 | sotorasib 960 mg daily | 16.6 | true | MSS | 2026-03-15T05:35:59.721880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180794 | REC_0011424 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.5 | 76 | male | 1 | 66 | 6.9 | 8 | pembrolizumab 200 mg q3w | 14 | true | MSS | 2026-03-15T05:35:59.722136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949457 | REC_0011425 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 32 | 11.8 | 64 | female | 1 | 14 | 5.1 | 0 | entrectinib 600 mg daily | 26.2 | false | MSS | 2026-03-15T05:35:59.722391+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948715 | REC_0011426 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 7.8 | 58 | female | 1 | 15 | 5.6 | 4 | osimertinib 80 mg daily | 14 | false | MSS | 2026-03-15T05:35:59.722634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_120454 | REC_0011427 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 32 | 5 | 69 | female | 1 | 14 | 6.1 | 4 | pembrolizumab 200 mg q3w | 5.7 | false | MSS | 2026-03-15T05:35:59.722873+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785351 | REC_0011428 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 10.7 | 72 | female | 2 | 9 | 5.7 | 7 | osimertinib 80 mg daily | 13.9 | true | MSI-H | 2026-03-15T05:35:59.723266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223467 | REC_0011429 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 11.9 | 55 | male | 1 | 16 | 4.9 | 7 | sotorasib 960 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:59.723518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837867 | REC_0011430 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 15.1 | 55 | male | 1 | 18 | 4.8 | 4 | sotorasib 960 mg daily | 6.1 | false | MSI-H | 2026-03-15T05:35:59.723764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537828 | REC_0011431 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 17.4 | 54 | female | 0 | 14 | 5.9 | 5 | alectinib 600 mg BID | 10.3 | true | MSS | 2026-03-15T05:35:59.724008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149165 | REC_0011432 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 34 | 8.6 | 65 | female | 1 | 8 | 6.2 | 7 | entrectinib 600 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:59.724389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_675602 | REC_0011433 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.9 | 67 | female | 0 | 23 | 7.9 | 5 | osimertinib 80 mg daily | 10.3 | false | MSS | 2026-03-15T05:35:59.724647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575329 | REC_0011434 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 9.6 | 74 | female | 2 | 23 | 6.7 | 6 | pembrolizumab 200 mg q3w | 7.6 | true | MSS | 2026-03-15T05:35:59.724892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730849 | REC_0011435 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 9.9 | 77 | female | 2 | 19 | 5 | 7 | osimertinib 80 mg daily | 9 | true | MSS | 2026-03-15T05:35:59.725140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341209 | REC_0011436 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 10.8 | 64 | female | 1 | 13 | 5.2 | 5 | sotorasib 960 mg daily | 15.6 | false | MSI-H | 2026-03-15T05:35:59.725415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192289 | REC_0011437 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 7.5 | 70 | male | 2 | 14 | 5.5 | 2 | sotorasib 960 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:59.725677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757040 | REC_0011438 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7.1 | 65 | female | 1 | 38 | 3.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 14.1 | false | MSS | 2026-03-15T05:35:59.726113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212566 | REC_0011439 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 9.7 | 62 | female | 0 | 18 | 3.6 | 5 | sotorasib 960 mg daily | 15.2 | true | MSS | 2026-03-15T05:35:59.726370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193231 | REC_0011440 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 6.5 | 71 | female | 2 | 32 | 6.9 | 1 | pembrolizumab 200 mg q3w | 27.4 | true | MSS | 2026-03-15T05:35:59.726605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_632695 | REC_0011441 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 17.2 | 86 | female | 2 | 11 | 8.1 | 8 | alectinib 600 mg BID | 10.3 | true | MSI-H | 2026-03-15T05:35:59.726991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836405 | REC_0011442 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 35 | 8.7 | 68 | female | 1 | 20 | 4.5 | 1 | pembrolizumab 200 mg q3w | 22.4 | false | MSS | 2026-03-15T05:35:59.727235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517085 | REC_0011443 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 3.6 | 58 | male | 1 | 56 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.5 | false | MSS | 2026-03-15T05:35:59.727477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457605 | REC_0011444 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 11.9 | 73 | female | 2 | 18 | 6.9 | 2 | alectinib 600 mg BID | 18.6 | true | MSI-H | 2026-03-15T05:35:59.727722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_911020 | REC_0011445 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 6 | 48 | female | 0 | 11 | 5.9 | 6 | osimertinib 80 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:59.727975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680611 | REC_0011446 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 15.2 | 74 | female | 2 | 12 | 4.5 | 2 | osimertinib 80 mg daily | 18 | false | MSI-H | 2026-03-15T05:35:59.728292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361531 | REC_0011447 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 12.9 | 56 | female | 0 | 12 | 4.3 | 1 | osimertinib 80 mg daily | 19.3 | false | MSS | 2026-03-15T05:35:59.728568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_821672 | REC_0011448 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 13.1 | 56 | male | 0 | 25 | 4.4 | 5 | sotorasib 960 mg daily | 14.6 | false | MSI-H | 2026-03-15T05:35:59.728867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466749 | REC_0011449 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 13.2 | 63 | male | 0 | 13 | 6.3 | 1 | osimertinib 80 mg daily | 11.6 | false | MSI-H | 2026-03-15T05:35:59.729172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837982 | REC_0011450 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 31 | 4.2 | 73 | female | 1 | 46 | 5.7 | 2 | pembrolizumab 200 mg q3w | 18.3 | false | MSS | 2026-03-15T05:35:59.729424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375132 | REC_0011451 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 6.9 | 66 | female | 1 | 3 | 6.2 | 5 | pembrolizumab 200 mg q3w | 8.8 | false | MSS | 2026-03-15T05:35:59.729659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719669 | REC_0011452 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 8.1 | 58 | female | 0 | 10 | 7.5 | 2 | pembrolizumab 200 mg q3w | 8.8 | false | MSS | 2026-03-15T05:35:59.729895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157828 | REC_0011453 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 16.3 | 59 | male | 1 | 5 | 5.4 | 2 | pembrolizumab 200 mg q3w | 23 | false | MSI-H | 2026-03-15T05:35:59.730132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572336 | REC_0011454 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.5 | 69 | female | 1 | 51 | 4.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.3 | false | MSS | 2026-03-15T05:35:59.730480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978915 | REC_0011455 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 14.9 | 62 | female | 1 | 14 | 5.4 | 6 | osimertinib 80 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:59.730727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449647 | REC_0011456 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.6 | 67 | female | 1 | 13 | 5.7 | 6 | entrectinib 600 mg daily | 16.4 | true | MSS | 2026-03-15T05:35:59.730958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157724 | REC_0011457 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 4.1 | 75 | female | 2 | 10 | 5.9 | 2 | alectinib 600 mg BID | 10 | false | MSS | 2026-03-15T05:35:59.731187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506367 | REC_0011458 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 10.7 | 69 | male | 1 | 14 | 5.5 | 1 | entrectinib 600 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:59.731421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472277 | REC_0011459 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 12.2 | 71 | male | 2 | 18 | 6.2 | 4 | osimertinib 80 mg daily | 8 | false | MSI-H | 2026-03-15T05:35:59.731658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627659 | REC_0011460 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 5.6 | 69 | female | 1 | 13 | 4.8 | 1 | alectinib 600 mg BID | 15.9 | true | MSS | 2026-03-15T05:35:59.731891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771622 | REC_0011461 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 4.4 | 62 | female | 0 | 8 | 5.6 | 6 | pembrolizumab 200 mg q3w | 7 | false | MSS | 2026-03-15T05:35:59.732170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142910 | REC_0011462 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 11.9 | 87 | female | 2 | 5 | 7.2 | 1 | entrectinib 600 mg daily | 14.8 | false | MSI-H | 2026-03-15T05:35:59.732411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149096 | REC_0011463 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 11 | 59 | male | 0 | 22 | 6 | 7 | alectinib 600 mg BID | 14.8 | true | MSI-H | 2026-03-15T05:35:59.732648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_526370 | REC_0011464 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 15.4 | 54 | female | 0 | 22 | 4.9 | 6 | osimertinib 80 mg daily | 11.4 | true | MSS | 2026-03-15T05:35:59.732880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307311 | REC_0011465 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 12 | 60 | male | 1 | 8 | 7.7 | 1 | entrectinib 600 mg daily | 16 | false | MSS | 2026-03-15T05:35:59.733118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388220 | REC_0011466 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 8.7 | 55 | female | 1 | 15 | 5.5 | 1 | sotorasib 960 mg daily | 17.7 | true | MSS | 2026-03-15T05:35:59.733353+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527145 | REC_0011467 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6 | 65 | female | 1 | 6 | 6.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.6 | true | MSS | 2026-03-15T05:35:59.733707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817004 | REC_0011468 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 12.4 | 60 | female | 1 | 20 | 7.1 | 2 | sotorasib 960 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:59.733995+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767472 | REC_0011469 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 11.1 | 64 | male | 1 | 18 | 3.7 | 6 | osimertinib 80 mg daily | 16.7 | true | MSI-H | 2026-03-15T05:35:59.734239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738210 | REC_0011470 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 13 | 64 | female | 0 | 21 | 5.6 | 7 | entrectinib 600 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:35:59.734475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383180 | REC_0011471 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 4.7 | 66 | female | 1 | 12 | 4.4 | 5 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:59.734708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174131 | REC_0011472 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 11.2 | 67 | male | 0 | 20 | 6.7 | 1 | alectinib 600 mg BID | 24.9 | true | MSS | 2026-03-15T05:35:59.734945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885156 | REC_0011473 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.3 | 72 | male | 1 | 54 | 4 | 7 | pembrolizumab 200 mg q3w | 13.2 | false | MSS | 2026-03-15T05:35:59.735178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277813 | REC_0011474 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 10 | 59 | male | 1 | 10 | 3.6 | 6 | entrectinib 600 mg daily | 18 | true | MSS | 2026-03-15T05:35:59.735412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143705 | REC_0011475 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 7.9 | 73 | female | 3 | 14 | 4 | 4 | sotorasib 960 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:59.735642+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822252 | REC_0011476 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 19.1 | 56 | male | 1 | 6 | 4.9 | 6 | entrectinib 600 mg daily | 5.5 | true | MSS | 2026-03-15T05:35:59.735876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757547 | REC_0011477 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 12.2 | 63 | female | 1 | 11 | 4.7 | 1 | osimertinib 80 mg daily | 22 | true | MSS | 2026-03-15T05:35:59.736154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201085 | REC_0011478 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 8.3 | 59 | male | 0 | 13 | 7.1 | 5 | pembrolizumab 200 mg q3w | 7.6 | true | MSS | 2026-03-15T05:35:59.736399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643078 | REC_0011479 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 10 | 69 | female | 0 | 11 | 6.3 | 1 | alectinib 600 mg BID | 24.4 | false | MSS | 2026-03-15T05:35:59.736636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792322 | REC_0011480 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.1 | 58 | male | 1 | 47 | 4.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.6 | true | MSS | 2026-03-15T05:35:59.736937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535642 | REC_0011481 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 11.1 | 71 | female | 2 | 14 | 5.9 | 5 | osimertinib 80 mg daily | 5.7 | false | MSI-H | 2026-03-15T05:35:59.737178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202410 | REC_0011482 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 12.4 | 76 | female | 2 | 25 | 6.7 | 6 | alectinib 600 mg BID | 11.7 | false | MSS | 2026-03-15T05:35:59.737415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136044 | REC_0011483 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.9 | 87 | female | 1 | 63 | 6.5 | 3 | carboplatin + paclitaxel + pembrolizumab | 15 | true | MSS | 2026-03-15T05:35:59.737652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140162 | REC_0011484 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 14.2 | 77 | female | 1 | 14 | 4.2 | 1 | sotorasib 960 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:35:59.737884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_619135 | REC_0011485 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 11.7 | 59 | female | 0 | 12 | 8.6 | 8 | alectinib 600 mg BID | 20.1 | true | MSI-H | 2026-03-15T05:35:59.738122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801430 | REC_0011486 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 9.4 | 75 | male | 1 | 43 | 7.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:35:59.738357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703538 | REC_0011487 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.9 | 76 | male | 2 | 54 | 4.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 5.8 | false | MSS | 2026-03-15T05:35:59.738588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290525 | REC_0011488 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 10.4 | 67 | female | 0 | 21 | 4.8 | 6 | alectinib 600 mg BID | 11.8 | true | MSI-H | 2026-03-15T05:35:59.738828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371818 | REC_0011489 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 5.7 | 66 | female | 0 | 13 | 5 | 5 | entrectinib 600 mg daily | 8.9 | false | MSS | 2026-03-15T05:35:59.739055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789216 | REC_0011490 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.1 | 58 | male | 1 | 6 | 5.7 | 6 | pembrolizumab 200 mg q3w | 10.6 | false | MSS | 2026-03-15T05:35:59.739286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755591 | REC_0011491 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 15.6 | 65 | male | 1 | 19 | 5.5 | 1 | osimertinib 80 mg daily | 15.6 | false | MSI-H | 2026-03-15T05:35:59.739521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703919 | REC_0011492 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 11.5 | 64 | male | 1 | 19 | 5.5 | 1 | sotorasib 960 mg daily | 19.3 | false | MSS | 2026-03-15T05:35:59.739755+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266639 | REC_0011493 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 10.7 | 59 | female | 1 | 16 | 4.6 | 9 | sotorasib 960 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:35:59.740036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117200 | REC_0011494 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 14.4 | 71 | female | 1 | 10 | 4.5 | 4 | osimertinib 80 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:35:59.740363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681238 | REC_0011495 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 7.7 | 49 | female | 0 | 22 | 5.2 | 1 | osimertinib 80 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:59.740609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853759 | REC_0011496 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 15.5 | 62 | male | 1 | 17 | 4 | 1 | entrectinib 600 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:35:59.740850+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362499 | REC_0011497 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 5.4 | 74 | female | 0 | 51 | 5.3 | 1 | pembrolizumab 200 mg q3w | 12.9 | false | MSS | 2026-03-15T05:35:59.741082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112993 | REC_0011498 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.8 | 63 | female | 0 | 26 | 6.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.2 | false | MSS | 2026-03-15T05:35:59.741316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395577 | REC_0011499 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 14.8 | 54 | male | 0 | 8 | 6.5 | 1 | osimertinib 80 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:59.741552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439217 | REC_0011500 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 8.6 | 84 | female | 2 | 12 | 6.6 | 2 | osimertinib 80 mg daily | 23.6 | true | MSS | 2026-03-15T05:35:59.741778+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.